BREAKING NEWS

Merck expands capacity at the Swiss biotech production site Aubonne

Expanded capacities support the expansion of the current and future portfolio of biotech drugs  The new building is used for visual inspection, secondary packaging and the dispatch of Merck biotechnology to more than 150 countries 27 million Swiss francs investment in the packaging building is part of a series of investments in Switzerland totaling 1 billion Swiss francs over the last 10 years   Merck, a leading science and technology company, today inaugurated a new packaging building at its Swiss biotech production site in Aubonne. At the inauguration ceremony, the chairman of the management and CEO of Merck , Stefan Oschmann , as well as representatives from local politics, business and science were present.     "This new, state-of-the-art packaging center demonstrates Merck's leading position in biotechnology," said Stefan Oschmann . "With our production sites in Aubonne and Vevey , Switzerland is our most important location for the production of biopharmaceutical drugs for patients all over the world, and is a key factor in the growth of our healthcare business and the launch of our new products."     The new building will be used to inspect, package and deliver biotechnologically manufactured medicines from the current Merck portfolio to more than 150 countries. It also creates capacities for ongoing and further possible future product launches.     Through process optimization, fully automatic operation and robotization of logistics, more than 12 million drug packs and 4 million injection systems can be handled each year in the new packaging building. It has been designed to meet the highest international quality, environmental and occupational safety standards.     A total of 27 million Swiss francs have been invested in the new packaging building between 2015 and 2017, with investments totaling more than CHF 1 billion over the past ten years in Switzerland. Merck currently employs more than 2,000 highly qualified employees at 11 locations throughout Switzerland, including more than 700 in Aubonne, where more than 200 jobs have been created over the last three years.     All press releases from Merck are also sent by e-mail at the same time as the publication on the Internet: Use the web address http://www.merck.de/newsabo to register online, change the selection made, or change the service Again to cancel.     About Merck Merck is a leading science and technology company in the fields of healthcare, life science and performance materials. Approximately 50,000 employees are working to develop technologies that enrich life - from biopharmaceutical therapies for the treatment of cancer or multiple sclerosis to pioneering systems for scientific research and production, to liquid crystals for smartphones or LCD televisions. In 2016, Merck generated sales of EUR 15.0 billion in 66 countries. Founded in 1668, Merck is the oldest pharmaceutical-chemical company in the world. The founding family is still the majority shareholder of the listed company. Merck, headquartered in Darmstadt, has the global rights to Merck's name and brand . The only exceptions are the US and Canada, where the company appears as EMD Serono, MilliporeSigma and EMD Performance Materials.

0 Comments Write your comment

    1. Loading...